Recruiting

Quit the Hit

Sponsor:

UCLA

Code:

NCT07540780

Conditions

Vaping

Vaping Cessation

Nicotine Dependence

Eligibility Criteria

Sex: All

Age: 13+

Healthy Volunteers: Accepted

Interventions

Social Media Intervention

Study Details

Brief summary:

The purpose of this study is to pilot test feasibility and acceptability of the Quit the Hit Toolkit, a social media-based nicotine vaping cessation program for adolescents and young adults, adapted for use in community settings.

Conditions

Vaping

Vaping Cessation

Nicotine Dependence

Study ID

NCT07540780

Start date

Apr 15, 2026

Status verified date

Jul, 2026

Completion date

Oct 31, 2026

Anticipated

Primary completion date

Sep 30, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 13+

Healthy Volunteers: Accepted

Inclusion Criteria:

1. English literacy
2. Age between 13-21 years (group participants) or 18+ (coaches, peer mentors)
3. Indicate they use social media "most" (>= 4) days per week (group participants)
4. Have vaped at least once per week in the past 30 days (90 percent of participants) (group participants)
5. Access to a computer or mobile phone with photo capability to verify abstinence from vaping (group participants)
6. Indicate they are considering quitting or are interested in quitting with the next 6 months or within the next 30 days (group participants)
7. Currently reside in California, Minnesota, Oklahoma, or South Carolina

Exclusion Criteria:

1. No English literacy
2. Age under 13 or over 21 (group participants) or under 18 (coaches, peer mentors)
3. Insufficient social media use (3 or fewer days per week) (group participants)
4. Have not vaped at least once per week in past 30 days (group participants)
5. No access to computer or mobile phone with photo capability to verify abstinence from vaping (group participants)
6. Not considering or interested in quitting vaping in the next 30 days or 6 months (group participants)
7. Not a resident of California, Minnesota, Oklahoma, or South Carolina

Study Design

Enrollment

60 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Vaping Intervention

Individuals will receive training on how to implement the vaping intervention (Quit the Hit Toolkit) in their own community settings. These individuals will serve as coaches and will recruit and facilitate vaping support groups on Instagram, where group participants will receive up to 3 Instagram posts per day for 30 days. Group coaches will work with a Cessation Counselor, Principal Investigator, Co-Investigators and a Pediatrician on demand if additional expertise or clinical advice is needed. Group participants will be educated about signs of nicotine dependence and if they express interest in pharmacotherapy will be encouraged to access this through their personal healthcare providers. The Instagram groups will provide educational and social support, troubleshooting and advice about nicotine replacement therapy (NRT) or other forms of treatment. Groups will also include trained peer mentors to provide additional support.

Interventions

Social Media Intervention

Social media based intervention using Instagram with up to 3 posts per day for 30 days

Primary outcome measure

  • Number of coaches who complete training and coach a vaping cessation group for 5 weeks [ Time Frame: 5 weeks ]

Central Contacts and Locations

Central contacts

Sarah Rosen, BA

415-502-0758quitthehit@ucsf.edu

Locations

University of California, San Francisco

Recruiting

San Francisco, California, United States, 94143

Contacts

Sarah Rosen, BA

415-502-0758quitthehit@ucsf.edu

Principal Investigator:

Pamela M Ling, MD, MPH

More Information

Sponsor

University of California, San Francisco

Last update posted

Jul 17, 2026

Last verified

Jul, 2026

Keywords

  • single arm
  • pilot
  • intervention
  • vaping
  • adolescent
  • young adult

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of California, San Francisco on 2026-07-17.